抗雄激素药物替换治疗对去势抵抗性前列腺癌患者前列腺特异抗原水平的影响  

Effect of antiandrogen replacement therapy on prostate specific antigen level in castration-resistant prostate cancer patients

作　　者：赵波[1] 张辉[1] ZHAO Bo;ZHANG Hui(Urology Surgery Department,the People's Hospital of Baoji,Baoji 721000,China)

机构地区：[1]宝鸡市人民医院泌尿外科,陕西宝鸡721000

出　　处：《临床医学研究与实践》2020年第29期26-28,共3页Clinical Research and Practice

摘　　要：目的探究抗雄激素药物替换治疗对去势抵抗性前列腺癌(CRPC)患者前列腺特异抗原(PSA)水平的影响。方法以2014年5月至2019年5月收治的120例CRPC患者为研究对象,其中60例患者经去势+氟他胺治疗无效后,更换比卡鲁胺治疗;60例患者经去势+比卡鲁胺治疗无效后,更换氟他胺治疗。分析CRPC患者替换治疗前、后的治疗效果、PSA、睾酮水平及不良反应发生情况。结果CRPC患者抗雄激素药物替换治疗后的治疗总有效率为91.67%,高于替换治疗前的69.17%(P<0.05)。CRPC患者抗雄激素药物替换治疗后的PSA、睾酮水平均明显低于替换治疗前(P<0.05)。CRPC患者抗雄激素药物替换治疗前、后的骨髓抑制、血小板减少、潮热、贫血、乳腺发育、肝肾功能损害、胃肠道反应发生率比较,差异无统计学意义(P>0.05)。结论CRPC患者接受抗雄激素药物替代治疗,能够更好地控制PSA、睾酮水平,提高其治疗效果,安全性高。Objective To investigate the effect of antiandrogen replacement therapy on prostate specific antigen(PSA)level in castration-resistant prostate cancer(CRPC)patients.Methods A total of 120 CRPC patients admitted from May 2014 to May 2019 were taken as research objects.Among them,60 patients were replaced with bicalutamide after failing to respond to castration+flutamide treatment,60 patients were replaced with flutamide after failing to castration+bicalutamide treatment.The treatment effect,PSA,testosterone levels and adverse reactions of CRPC patients before and after replacement therapy were analyzed.Results The total effective rate of treatment in CRPC patients after antiandrogen drug replacement therapy was 91.67%,which was higher than 69.17%before replacement therapy(P<0.05).The levels of PSA and testosterone in patients with CRPC after antiandrogen drug replacement therapy were significantly lower than those before replacement therapy(P<0.05).There were no significant differences in the incidences of myelosuppression,thrombocytopenia,hot flashes,anemia,breast development,liver and kidney function damage,gastrointestinal reaction in patients with CRPC before and after antiandrogen drug replacement treatment(P>0.05).Conclusion Patients with CRPC receiving antiandrogen drug replacement therapy can better control the levels of PSA and testosterone,improve the therapeutic effect,and have high safety.

关 键 词：抗雄激素药物 去势抵抗性前列腺癌 前列腺特异抗原 去势治疗 睾酮 

分 类 号：R737.25[医药卫生—肿瘤]